D&D Pharmatech Inc. (KOSDAQ: 347850)

Market Cap	355.16B
Revenue (ttm)	13.24B
Net Income (ttm)	-10.55B
Shares Out	10.54M
EPS (ttm)	-2,610.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	440,433
Open	34,200
Previous Close	33,600
Day's Range	32,900 - 36,350
52-Week Range	25,100 - 53,900
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About D&D Pharmatech

D&D Pharmatech Inc., a clinical-stage biotech company, develops medicines in South Korea and the United States. It develops NLY01-PD, NLY01-AD, and NLY01-D that are in Phase II clinical trials for the treatment of Parkinson’s disease (PD), Alzheimer’s disease (AD), and type 2 diabetes; and P4M01, which has completed Phase IIa clinical trials to treat periodontal disease. The company also develops DD01 that is in Phase I clinical trials for the treatment of obesity/diabetes/nonalcoholic steatohepatitis (NASH); TLY012, which is Phase I clinical t...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 21
• Stock Exchange: KOSDAQ
• Ticker Symbol: 347850